Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 oct. 2013 04h00 HE | Source: Pluri Inc.

Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel

HAIFA, Israel, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Israeli Ministry...
01 oct. 2013 03h00 HE | Source: Pluri Inc.

Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host Disease

Both Intramuscular and Intravenous Administrations Show Statistically Significant Improvement Clinical Path Being Investigated With Leading Medical Institutions HAIFA, Israel, Oct. 1, 2013...
16 sept. 2013 03h00 HE | Source: Pluri Inc.

FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study

HAIFA, Israel, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and...
11 sept. 2013 03h00 HE | Source: Pluri Inc.

Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease

HAIFA, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has...
14 août 2013 03h00 HE | Source: Pluri Inc.

Tendon Injuries Treated With Pluristem's PLX Cells Demonstrate Favorable Properties

HAIFA, Israel, Aug. 14, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the results of a...
06 août 2013 04h00 HE | Source: Pluri Inc.

Pluristem Awarded a $3.3 Million Grant by Israeli Government

HAIFA, Israel, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 12...
18 juil. 2013 04h00 HE | Source: Pluri Inc.

U.S. National Institutes of Health Recommend to Expand Its Scope of Research in the Development of Pluristem's PLX-RAD Cells for the Treatment of Acute Radiation Syndrome

HAIFA, Israel, July 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. National...
11 juil. 2013 03h00 HE | Source: Pluri Inc.

Pluristem Completes Enrollment for Phase I/II Muscle Injury Trial

HAIFA, Israel, July 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has completed the...
08 juil. 2013 03h00 HE | Source: Pluri Inc.

Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

HAIFA, Israel, July 8, 2013 (GLOBE NEWSWIRE) -- On the heels of announcing its strategic partnership agreement with Cha Bio&Diostech (Kosdaq:CHA) on June 26th, Pluristem Therapeutics Inc....
26 juin 2013 03h00 HE | Source: Pluri Inc.

Pluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercialization of PLX Cells for the Treatment of CLI and IC in South Korea

HAIFA, Israel, June 26, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive...

Page précédente